Applied dna positions tr8 pgx testing service as pre-emptive testing for safety of fluoropyrimidine-based cancer therapeutics following publication of food and drug administration safety announcement

- company revamps pharmacogenomics go-to-market strategy, targets validated pgx assay towards specific use cases - stony brook, ny / access newswire / april 1, 2025 / applied dna sciences, inc. (nasdaq:apdn) (applied dna or the "company"), a leader in pcr-based dna technologies, today announced that applied dna clinical labs (adcl), its wholly-owned clinical laboratory subsidiary, is repositioning its tr8™ pgx pharmacogenomics testing service to offer tailored subpanels for indication-specific use cases in addition to full panel testing. the first subpanel under adcl's new go-to-market strategy is for the pre-emptive testing of patients with genetic variants of the dpyd gene that correlate to potentially reduced or absent dpd enzyme activity necessary to metabolize fluoropyrimidines, specifically capecitabine (branded xeloda) and fluorouracil (5-fu), two chemotherapy drugs that are widely used as part of the standard of care treatment for patients with certain cancers.
APDN Ratings Summary
APDN Quant Ranking